FY2026 EPS Estimates for Oculis Cut by Lifesci Capital

Oculis Holding AG (NASDAQ:OCS) – Equities research analysts at Lifesci Capital decreased their FY2026 earnings per share (EPS) estimates for shares of Oculis in a note issued to investors on Thursday, May 7th. Lifesci Capital analyst P. Dolezal now anticipates that the company will post earnings per share of ($1.90) for the year, down from their previous forecast of ($1.89). The consensus estimate for Oculis’ current full-year earnings is ($2.17) per share.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.07). Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%.The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million.

A number of other brokerages also recently weighed in on OCS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright restated a “buy” rating and issued a $44.00 target price on shares of Oculis in a research note on Monday, April 20th. Needham & Company LLC raised their target price on Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Stifel Nicolaus raised their target price on Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.86.

Oculis Stock Performance

Shares of Oculis stock opened at $32.65 on Tuesday. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $27.18 and a two-hundred day moving average price of $24.33. Oculis has a 1-year low of $16.00 and a 1-year high of $34.47. The company has a market cap of $1.89 billion, a P/E ratio of -14.38 and a beta of 0.38.

Institutional Trading of Oculis

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares in the last quarter. Marshall Wace LLP bought a new position in Oculis in the 2nd quarter valued at about $393,000. Bank of America Corp DE lifted its position in Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares in the last quarter. Woodline Partners LP lifted its position in Oculis by 65.8% in the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after acquiring an additional 33,265 shares in the last quarter. Finally, Aventura Private Wealth LLC bought a new position in Oculis in the 4th quarter valued at about $80,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.